Medicines & Healthcare products Regulatory Agency

MHRA

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Prof C Butler
UNIVERSITY OF OXFORD
NUFFIELD DEPARTMENT OF PRIMARY CARE HEALTH SCIENCES,
RADCLIFFE OBSERVATORY QUARTER, WOODSTOCK ROAD
OXFORD
OX2 6GG
UNITED KINGDOM

19/11/2021

Dear Prof C Butler,

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our reference:	CTA 21584/0452/001-0001
Eudract Number:	2021-005748-31
Product:	Molnupiravir
Protocol number:	PANORAMIC

NOTICE OF ACCEPTANCE

I am writing to inform you that the Licensing Authority accepts your request for a clinical trial authorisation (CTA), received on 10/11/2021.

The authorisation is effective from the date of this letter although your trial may be suspended or terminated at any time by the Licensing Authority in accordance with regulation 31. You must notify the Licensing Authority within 90 days of the trial ending.

You are reminded that a favourable opinion from the Ethics Committee is also required before this trial can proceed. If not already provided, please follow the guidance on our website on informing us of the registration status of your trial (where applicable).

You are reminded that from 1 January 2022 you will need to comply with the requirements specified in the following guidance, where applicable:

- ***Import of IMPs from listed countries to GB:***

https://www.gov.uk/government/publications/importing-investigational-medicinal-products-into-great-britain-from-approved-countries

- ***Supply of IMPs to Northern Ireland:***

https://www.gov.uk/guidance/supplying-investigational-medicinal-products-to-northern-ireland

- ***Substantial amendments to clinical trials:***

https://www.gov.uk/guidance/guidance-on-substantial-amendments-to-a-clinical-trial

Medicines & Healthcare products Regulatory Agency

MHRA

Any required substantial amendment to your Clinical Trial Authorisation should be submitted and approved as soon as possible and before 1 January 2022.

Yours sincerely,

Clinical Trials Unit
MHRA